Based on the BIOND.PHAR.ADS/400 IL-01 stock forecast from 0 analysts, the average analyst target price for BIOND.PHAR.ADS/400 IL-01 is not available over the next 12 months. BIOND.PHAR.ADS/400 IL-01’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BIOND.PHAR.ADS/400 IL-01 is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, BIOND.PHAR.ADS/400 IL-01’s stock price was EUR 0.408. BIOND.PHAR.ADS/400 IL-01’s stock price has changed by +2.51% over the past week, -5.99% over the past month and -74.50% over the last year.
No recent analyst target price found for BIOND.PHAR.ADS/400 IL-01
No recent average analyst rating found for BIOND.PHAR.ADS/400 IL-01
Company Overview BIOND.PHAR.ADS/400 IL-01
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel. Read Less
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaborat...Read More
Frequently Asked Questions About BIOND.PHAR.ADS/400 IL-01 (2F50:F) Stock
Stock Target Advisor's fundamental analysis for BIOND.PHAR.ADS/400 IL-01's stock is Very Bearish.
Unfortunately we do not have enough data on 2F50:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 2F50:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 2F50:F's stock to indicate if its overvalued.
The last closing price of 2F50:F's stock was EUR 0.41.
The most recent market capitalization for 2F50:F is EUR 1.91M.
Unfortunately we do not have enough analyst data on 2F50:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains BIOND.PHAR.ADS/400 IL-01's stock.
As per our most recent records BIOND.PHAR.ADS/400 IL-01 has 33 Employees.
BIOND.PHAR.ADS/400 IL-01's registered address is Jerusalem BioPark Building, Jerusalem, Israel.
You can get more information about it from BIOND.PHAR.ADS/400 IL-01's website at https://www.scinai.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 2F50:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
